Somewhat Favorable News Coverage Somewhat Unlikely to Affect Verona Pharma plc – American Depositary Share (VRNA) Share Price

News articles about Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Verona Pharma plc – American Depositary Share earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.1314100181523 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) traded up $0.61 during mid-day trading on Friday, reaching $11.91. The company had a trading volume of 700 shares, compared to its average volume of 5,762. Verona Pharma plc – American Depositary Share has a 52-week low of $10.44 and a 52-week high of $17.50.

Several brokerages recently issued reports on VRNA. Wedbush reaffirmed a “buy” rating and set a $33.00 price objective on shares of Verona Pharma plc – American Depositary Share in a report on Friday, December 8th. Zacks Investment Research cut Verona Pharma plc – American Depositary Share from a “hold” rating to a “sell” rating in a report on Friday, November 10th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Verona Pharma plc – American Depositary Share currently has a consensus rating of “Buy” and a consensus price target of $24.20.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://weekherald.com/2017/12/29/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-verona-pharma-plc-american-depositary-share-vrna-share-price.html.

Verona Pharma plc – American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Insider Buying and Selling by Quarter for Verona Pharma plc - American Depositary Share (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply